tVNS by indication
The tVNS® device holds Class IIa certification under EU MDR 2017/745 with approved indications across four condition areas. Each condition has its own clinical page in this zone, written for healthcare professionals who already know the field.
The pages are not promotional. They are written so that a clinician evaluating tVNS for a specific patient can read one page and come away with what they need to make an informed decision: the pathophysiological rationale, the strongest controlled trial evidence, candidate selection criteria, parameter recommendations, expected time course, and the questions that remain open.
Where the evidence is strong, we say so. Where it is thinner, we say that too.
Approved indications
Epilepsy
The longest-running and best-evidenced indication for vagus nerve stimulation in any form. Two substantial randomised controlled trials, multiple pilot studies, real-world cohort data over one to two years, and two meta-analyses now support a non-invasive alternative to implanted VNS for drug-resistant epilepsy. In the largest controlled trial, just under 45% of participants achieved at least a 50% reduction in seizures, versus about 17% on control; uncontrolled real-world cohorts report higher figures (around 62%), but without a control arm these are not directly comparable. No serious adverse events have been attributed to the device in the controlled trials cited.
Read the clinician page on tVNS for epilepsy
Depression
Vagus nerve stimulation has been used as an adjunctive treatment for treatment-resistant depression since the early 2000s in its implanted form. The transcutaneous form is younger as a depression treatment, with smaller trials and more variability between studies, but the mechanistic rationale (noradrenergic and serotonergic modulation through brainstem relays) is shared with implanted VNS, and the early controlled data is encouraging.
Read the clinician page on tVNS for depression
Migraine
Cervical transcutaneous vagus nerve stimulation has regulatory clearance for migraine and cluster headache in several regions, with the strongest data in episodic cluster headache. Auricular tVNS through the cymba conchae has a smaller migraine literature, but the mechanism (modulation of trigeminal-vagal convergence in the spinal trigeminal nucleus and descending pain inhibition) is consistent with the cervical evidence. The picture is mixed but moving in a constructive direction.
Read the clinician page on tVNS for migraine
Prader-Willi syndrome
The rarest of the four indications and the one with the smallest published evidence base. EU MDR approval is specifically for temper outbursts, which are among the most distressing behavioural features of the condition for families and care teams. The published case series and pilot data are limited, and we are honest about that on the page itself. We include the indication because it is regulated, because we work with families and clinical teams who have used the device, and because the alternative is silence, which serves nobody.
Read the clinician page on tVNS for Prader-Willi syndrome
How the pages are structured
Each clinician condition page follows the same structure, so you can find the section you want without reading the whole document.
- The clinical context. Who the indication applies to, the burden of disease, the place tVNS occupies in the existing care pathway.
- Mechanism. The pathways that matter for this specific condition. This is shorter on the per-condition pages than on the overview, which carries the full mechanistic discussion.
- The evidence. The trials, the meta-analyses, the real-world data, and the limitations.
- Comparison with alternatives. Where appropriate, a comparison with implanted VNS, with cervical tVNS, or with the standard pharmacological options.
- Practical guidance. Candidate selection, contraindications, dosing parameters, initiation protocol, what to tell the patient, what to monitor.
- Safety. Common, uncommon, and rare adverse events specific to this indication.
- Regulatory and access context. UK distribution, NICE position, prescriber considerations.
- What we do not yet know. The honest gaps.
- Summary. The clinical bottom line in one paragraph.
If you would prefer to start with the framework rather than a specific indication, the clinician overview covers the mechanism and the anatomical case for the cymba conchae. The practice guide covers the operational side: selection, parameters, monitoring, and the trial structure that applies across indications.
Off-label and emerging applications
Several conditions outside the four approved indications have a credible mechanistic rationale and a small but growing trial base. We do not market the device for any of these, and any off-label use is a clinical decision that sits with the prescribing clinician.
The conditions where the published research is most active include stroke rehabilitation, particularly for upper limb motor recovery and for swallowing function; functional gastrointestinal disorders, where the brain-gut axis provides a rationale; spinal cord injury, where vagal modulation may have a role in autonomic regulation and inflammation; and chronic pain, where the convergence of vagal afferents with descending pain inhibitory pathways is plausible.
We are happy to share the relevant literature on request. If you are considering tVNS in an off-label context for a specific patient and want to discuss the published evidence, contact us.
tVNS is a Class IIa medical device manufactured by tVNS Technologies GmbH, Germany. Distributed in the UK by Anatomical Concepts UK Ltd. Class IIa indications include epilepsy, depression, migraine, and Prader-Willi syndrome among others.